NCT04147325View on ClinicalTrials.gov

A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1

CompletedOBSERVATIONAL

Enrollment

105

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions

HIV

Interventions

DRUG

Antiretroviral Therapy

ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.

Trial Locations (1)

1349-019

Chlo - Hosp. Egas Moniz, Lisbon

All Listed Sponsors

lead

Janssen-Cilag Farmaceutica Ltda.

INDUSTRY

NCT04147325 - A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1 | Biotech Hunter | Biotech Hunter